Teva CFO Sees New Products Coming From Its NTEs & Israel’s R&D Hub
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva’s CFO says the world’s top generics maker is entering a growth period buoyed by emerging markets and an expanding pipeline that will include re-purposed drugs, allowing the company to offset revenue lost from patent expiries. He also believes innovative R&D in home market Israel will soon enjoy a renaissance.
You may also be interested in...
Protonix Settlement Leaves Question Of How Jury Would Assess At-Risk Launch Damages
Teva and Sun are to pay $2.15 billion for their at-risk launch of generic versions of Pfizer’s Protonix; Pfizer says figure represents lost profits and lost royalties from the three years the product faced premature generic competition.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.